Route 92’s Neurovascular Portfolio Approved in Canada

Route 92 Medical Announces First Commercial Cases in Canada

Procedures follow Health Canada Medical Device License for the Company’s advanced neurovascular portfolio

Route 92’s Neurovascular Portfolio Approved in Canada

June 22, 2026—Route 92 Medical, Inc. announced that the first commercial cases in Canada were performed with the company’s neurovascular devices. The procedures used the company’s HiPoint 88 system and its Monopoint approach. The procedures came after receipt of a Health Canada Medical Device License for the company’s portfolio of neurovascular technologies, which includes the HiPoint 70/Tenzing 7 reperfusion system, HiPoint 88/Tenzing 8 reperfu…